225 related articles for article (PubMed ID: 9384467)
1. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation.
Schmider J; Greenblatt DJ; von Moltke LL; Karsov D; Shader RI
Br J Clin Pharmacol; 1997 Nov; 44(5):495-8. PubMed ID: 9384467
[TBL] [Abstract][Full Text] [Related]
2. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Ball SE; Ahern D; Scatina J; Kao J
Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors.
Nelson MH; Birnbaum AK; Remmel RP
Epilepsy Res; 2001 Apr; 44(1):71-82. PubMed ID: 11255075
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.
Hemeryck A; De Vriendt C; Belpaire FM
Eur J Clin Pharmacol; 1999 Feb; 54(12):947-51. PubMed ID: 10192756
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
6. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine.
Giancarlo GM; Venkatakrishnan K; Granda BW; von Moltke LL; Greenblatt DJ
Eur J Clin Pharmacol; 2001 Apr; 57(1):31-6. PubMed ID: 11372587
[TBL] [Abstract][Full Text] [Related]
7. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively.
Wen X; Wang JS; Backman JT; Laitila J; Neuvonen PJ
Drug Metab Dispos; 2002 Jun; 30(6):631-5. PubMed ID: 12019187
[TBL] [Abstract][Full Text] [Related]
8. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
9. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
Preskorn SH
Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
[TBL] [Abstract][Full Text] [Related]
10. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
Gentile DM; Verhoeven CH; Shimada T; Back DJ
J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282
[TBL] [Abstract][Full Text] [Related]
11. Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine.
Ring BJ; Eckstein JA; Gillespie JS; Binkley SN; VandenBranden M; Wrighton SA
J Pharmacol Exp Ther; 2001 Jun; 297(3):1044-50. PubMed ID: 11356927
[TBL] [Abstract][Full Text] [Related]
12. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes.
Bourrié M; Meunier V; Berger Y; Fabre G
Drug Metab Dispos; 1999 Feb; 27(2):288-96. PubMed ID: 9929518
[TBL] [Abstract][Full Text] [Related]
13. Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: difference in chiral preference of CYP2C9 and CYP2C19.
Yasumori T; Chen LS; Li QH; Ueda M; Tsuzuki T; Goldstein JA; Kato R; Yamazoe Y
Biochem Pharmacol; 1999 Jun; 57(11):1297-303. PubMed ID: 10230773
[TBL] [Abstract][Full Text] [Related]
14. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A.
Ring BJ; Binkley SN; Vandenbranden M; Wrighton SA
Br J Clin Pharmacol; 1996 Mar; 41(3):181-6. PubMed ID: 8866916
[TBL] [Abstract][Full Text] [Related]
15. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.
Tang C; Shou M; Mei Q; Rushmore TH; Rodrigues AD
J Pharmacol Exp Ther; 2000 May; 293(2):453-9. PubMed ID: 10773015
[TBL] [Abstract][Full Text] [Related]
16. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6.
Voorman RL; Payne NA; Wienkers LC; Hauer MJ; Sanders PE
Drug Metab Dispos; 2001 Jan; 29(1):41-7. PubMed ID: 11124228
[TBL] [Abstract][Full Text] [Related]
17. Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system.
Ereshefsky L; Riesenman C; Lam YW
J Clin Psychiatry; 1996; 57 Suppl 8():17-24; discussion 25. PubMed ID: 8698676
[TBL] [Abstract][Full Text] [Related]
18. Effect of selective serotonin reuptake inhibitors on the oxidative metabolism of propafenone: in vitro studies using human liver microsomes.
Hemeryck A; De Vriendt C; Belpaire FM
J Clin Psychopharmacol; 2000 Aug; 20(4):428-34. PubMed ID: 10917404
[TBL] [Abstract][Full Text] [Related]
19. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants.
von Moltke LL; Greenblatt DJ; Court MH; Duan SX; Harmatz JS; Shader RI
J Clin Psychopharmacol; 1995 Apr; 15(2):125-31. PubMed ID: 7782485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
